MDN1

Across TCGA pan-cancer cohorts, MDN1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MDN1’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where MDN1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MDN1 is over-expressed in tumor, although a few such as PDAC and CCRCC show the opposite, repressed pattern.

LSCC, HNSC, and LUAD are the cancer types where MDN1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MDN1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	+0.453	<.001	8	view →
HNSC	Male	III,IV	+0.259	<.001	8	view →
LUAD	Male	All	+0.131	<.001	7	view →
PDAC	Female	II,III,IV	−0.524	<.001	6	view →
CCRCC	All	All	−0.092	<.001	6	view →
COAD	Female	IV	−0.245	.007	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MDN1–LSCC

Open the LSCC breakdown →